Melanoma Insights for Professionals Melanoma Institute Australia

Mucosal melanoma is a rare and aggressive form of melanoma that arises from the mucous membrane.

In this podcast, we focus on mucosal melanoma of the head and neck. Led by A/Prof Sydney Ch’ng, our multidisciplinary experts discuss how it differs from cutaneous melanoma, staging of mucosal melanoma, management of the disease and future treatments.

The discussion concludes with a case study to summarise key learnings.

This podcast is suitable for Plastic Surgeons, Surgical Oncologists, Dermatologists, Medical Oncologists, Pathologists, GPs, Nurses and other healthcare professionals.

Register now to attend the 2024 Australasian Melanoma Conference, hosted by Melanoma Institute Australia.



SPEAKERS


A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney
Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney
A/Prof Raewyn Campbell - Rhinologist and Anterior Skull Base Surgeon |Associate Professor, Macquarie University
Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital
Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney



Please note that this podcast was accurate at the time of recording (March 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

Diagnostic uncertainty in the context of cutaneous melanoma can have significant impact on patient care.

In this podcast, our multidisciplinary experts, led by Dr Adrian Quek, discuss the challenges faced in classifying melanocytic lesions that fall into a diagnostic grey area, and explore the terminology, evolving classifications and the impact of diagnostic uncertainty on patient outcomes.

From molecular changes to clinical perspectives, this engaging discussion provides a comprehensive exploration of the complexities surrounding borderline lesions, and emphasises the need for experienced multidisciplinary professionals in ensuring accurate diagnoses and ideal management.

This podcast is suitable for Pathologists, Dermatologists, Surgeons, Oncologists, GPs and other healthcare professionals.


Register now to attend the ⁠2024 Australasian Melanoma Conference⁠, hosted by Melanoma Institute Australia.

RESOURCES


Video: How to diagnose borderline cutaneous melanocytic lesions


Paper: Yeh, I. New and evolving concepts of melanocytic nevi and melanocytomas. Modern Pathology. 2020;33:1-14.


Nevus/Melanocytoma/Melanoma: An Emerging Paradigm for Classification of Melanocytic Neoplasms?. Arch Pathol Lab Med. 2011;135(3): 300–306.



SPEAKERS


Dr Adrian Quek - Skin Cancer GP, Melanoma Institute Australia and Chatswood Skin Cancer Clinic
A/Prof Robyn Saw - General Surgeon, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of Sydney
Prof H. Peter Soyer - Chair in Dermatology and Director of the Dermatology Research Centre, The University of Queensland
Dr Andrew Colebatch - Staff Specialist in Anatomical Pathology, Royal Prince Alfred Hospital



Please note that this podcast was accurate at the time of recording (November 2023) but may
not reflect the rapidly evolving treatment landscape and approvals in Australia.


MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.



For more clinical education from MIA, sign up to the Melanoma Education Portal.

With the advent of effective medical therapies for melanoma, a pertinent question has arisen: When should we scan our patients?

In this podcast, our multidisciplinary experts, led by A/Prof Sydney Ch’ng, discuss the balance of whether we should be more aggressive in our pursuit of identifying potential metastases or exercise caution to avoid unnecessary scans, radiation exposure and patient anxiety. The discussion concludes with a case study to summarise key learnings.

This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, GPs, Oncology Nurses and other healthcare professionals.



RESOURCES

Melanoma Risk Prediction Tools



SPEAKERS




A/Prof Sydney Ch’ng -  Plastic & Reconstructive
Surgeon and Head & Neck Surgeon, Melanoma Institute Australia, Associate Professor of Surgery, The University of Sydney 


A/Prof Alexander Menzies -  Medical Oncologist,
Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney


A/Prof Alexander van Akkooi - Associate Professor in
Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney


Dr Edward Hsiao - Radiologist and Nuclear Medicine Specialist, Mater Imaging
Dr Kevin London - Nuclear Medicine Specialist, The Children’s Hospital at Westmead | Clinical Senior Lecturer, The University of Sydney

Please note that this podcast was accurate at the time of recording (September 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.


For more practice-changing education, visit our Melanoma Education Portal.


MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. 

Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas.

In this fireside chat from our new SNB Training Program (Sentinel Node Biopsy: From guidelines to practice), MIA’s Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch’ng discuss:


the history of SNB in the management of melanoma
its current role in the stratification of patients into those who may benefit from adjuvant therapies verses those for whom active surveillance is more appropriate
other potential benefits of SNB, including the likelihood of SNB itself reducing the risk of nodal recurrence.

This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals.



SPEAKERS


A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney
Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney
Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia



Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Our latest podcast explores the innovative approach of neoadjuvant  immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of  melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential  benefits for melanoma patients are being realised.

Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates.

In this engaging podcast, MIA’s Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss:


the benefits of checkpoint inhibitor immunotherapy
the role of the pathologist in the assessment of neoadjuvant tissue
the impact of surgical decision-making as neoadjuvant becomes mainstay treatment
options for treatment-refractory patients
the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer.

The discussion concludes with case studies to summarise key learnings.

This podcast is suitable for Medical Oncologists, Oncologists,  Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other  healthcare professionals.

SPEAKERS:


Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and  Translational Research, Melanoma Institute Australia and Royal North  Shore Hospital, The University of Sydney
Prof Richard Scolyer AO - Co-Medical Director,  Melanoma Institute Australia | Pathologist, Melanoma Institute  Australia, Senior Staff Specialist, Royal Prince Alfred Hospital |  Clinical Professor, The University of Sydney
A/Prof Alexander Menzies - Medical Oncologist,  Melanoma Institute Australia, Royal North Shore and Mater Hospitals |  Associate Professor of Melanoma Medical Oncology, The University of  Sydney
A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal  Prince Alfred Hospital, The University of Sydney

KEY CLINICAL TRIALS


SWOG
PRADO
OpACIN-neo
NADINA

FURTHER EDUCATION


The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists 

Please note that this podcast was accurate at the time of recording  (February 2023) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians.

In this podcast, Dr Michael Rtshiladze leads a multidisciplinary  discussion to unravel our understanding of the pathology, diagnosis and  management of lentigo maligna, including:


clinical and histological presentation
tools to diagnose and monitor lesions
the impact of different types of biopsies
the importance of mapping the extent of lesions
the challenge of surgical management in cosmetically sensitive areas
the role of radiation therapy and topical treatments
when to refer your patient.

The discussion concludes with a case study to summarise key learnings.

This podcast is suitable for Plastic Surgeons, General Surgeons,  Dermatologists, Oncologists, Pathologists, GPs, Nurses and other  healthcare professionals.

SPEAKERS


Dr Michael Rtshiladze - Plastic and Reconstructive  Surgeon, Melanoma Institute Australia, Royal Prince Alfred Hospital, The  Prince of Wales Hospital, St George Hospital and Sydney Children’s  Hospital
Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital
Prof Pascale Guitera - Dermatologist, Melanoma  Institute Australia | Director, Sydney Melanoma Diagnostic Centre at  Royal Prince Alfred Hospital | Professorial Research Fellow, The  University of Sydney
Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney

RESOURCE AND REFERENCE


Lentigo Maligna Patient Information Brochure
Crouch G, Sinha S, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, Scolyer RA, Thompson JF & Ch'ng S. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. Eur J Surg Oncol. 2021 May;47(5):1145-1151.

Please note that this podcast was accurate at the time of recording  (December 2022) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.